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Islet Inflammation: The Link 




The role of islet inflammation in type 2 diabetes (T2DM) and pancreatic ductal 
adenocarcinoma (PDAC) is complex. About 80% of pancreatic cancer patients have 
glucose intolerance or T2D. Chronic type 2 diabetes increases risk for pancreatic 
cancer, but the mechanisms are unknown. In this context two hypotheses exist: 
(i) pancreatic cancer causes diabetes and (ii) diabetes promotes the development 
of pancreatic cancer. Pancreatic ductal adenocarcinoma is the most common and 
deadly form of pancreatic cancer that is associated with diabetes. There are many 
possibilities by which obesity links to pancreatic cancer. These possibilities include 
insulin resistance, hyperinsulinemia and inflammation. Adipose tissue deposition 
near pancreas (peri-pancreatic depot) increase proinflammatory response to a 
high fat or high calorie containing diet. Inflammatory processes in the islets act 
as main mediators during the development and progression of pancreatic cancer. 
Recently, studies have been carried out to investigate the underlying mechanisms 
that contribute to tumorigenesis induced by inflammation. Tumor-elicited inflam-
mation, secretion of pro-inflammatory cytokines and migration of immune cells 
play the key roles in initiation, promotion and progression of malignant metastasis 
in pancreatic cancer. Initiation and progression of islet inflammation in diabetes 
and pancreatic cancer occurs as a result of various protein–protein interactions 
and genetic events. The increase in pancreatic cancer cases may be attributed to 
the obesity endemic and obesity mediated Type 2 diabetes. The existence of link 
between islet inflammation in chronic diabetes and pancreatic cancer cannot be 
ignored, although the details about the underlying mechanisms are not clear, and 
must be studied in detail.
Keywords: Islet inflammation, type 2 diabetes, pancreatic cancer, obesity,  
insulin resistance
1. Introduction
Type 2 diabetes (T2D) is characterized by hyperglycemia which occurs due to 
impaired insulin production and reduced pancreatic beta cell population during 
insulin resistance. Most diabetes patients are able to compensate increasing insulin 
resistance by increasing insulin production. Now the decrease in insulin secre-
tion occurs due to increased beta cell apoptosis, and the reason behind apoptosis 
remains endoplasmic reticulum stress, mitochondrial dysfunction and inflam-
mation. Since a long time T2D and pancreatic cancer have been associated and 
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development of diabetes is related to occurrence of pancreatic cancer. The causes 
behind association of T2D with pancreatic cancer may be chronic inflammation 
and common progenitor cells for endocrine and exocrine pancreas, however still 
more research is needed in this field, and every detail about diabetes and pancreatic 
cancer must be studied [1].
Firstly, Type 2 diabetes is the third most possible risk factor for pancreatic 
cancer after obesity and cigarette smoking. Studies have shown that chronic type 2 
diabetes increases risk of pancreatic cancer by 1.5- to 2.0-fold. Prediagnostic assess-
ment of glucose and insulin levels may help in early diagnosis. The reasons behind 
development of diabetes-associated pancreatic cancer remain insulin resistance, 
hyperglycemia, hyperinsulinemia, and inflammation. On the other hand, people 
diagnosed with Type 2 diabetes may be part of a population of pancreatic cancer 
patients who have been detected earlier. There are several signaling pathways regu-
lating metabolic processes which dictate cell proliferation and tumor growth. Better 
insight on the different mechanisms common in Type 2 diabetes and pancreatic 
cancer can be helpful in the development of new biomarkers and potent preventive 
or therapeutic strategies [1].
Ductal adenocarcinoma of pancreas is the fifth major cause of death in cancer 
in developed countries after lung, stomach, colorectal and breast cancer. 23% of 
the patients can live for 1 year after diagnosis and 6% of the patients have a 5-year 
survival rate due to advanced stage of cancer at the time of the diagnosis. Ductal 
adenocarcinoma of pancreas is also the thirteenth most common type of cancer and 
eight most common cause of cancer-related deaths. Here it must be mentioned that 
80% of pancreatic cancer patients have been ailing with Type 2 diabetes or compro-
mised glucose tolerance at the time of diagnosis [2–4].
Patients with ductal adenocarcinoma of pancreas and also Type 2 diabetes, have 
a record of diagnosis of diabetes less than 24 months before the diagnosis of ductal 
adenocarcinoma of pancreas in 74–88% of cases [5]. It means that Type 2 diabetes 
and ductal adenocarcinoma of pancreas show “dual causality,” while chronic Type 
2 diabetes remains a risk factor for the development of ductal adenocarcinoma of 
pancreas and, on the other hand, ductal adenocarcinoma of pancreas is also pre-
sumed to be a cause for Type 2 diabetes in many cases.
The Centre for Disease Control and Prevention recorded that ~29 million people 
in the U.S. suffered from Type 2 diabetes in 2014, while about 8 million of these 
patients have not yet been diagnosed. Also, ~86 million adults in the U.S. are known 
to be prediabetic, having a fasting plasma glucose level of 100–125 mg/dL, a 2-h 
plasma glucose level of 140–199 mg/dL, or a glycohemoglobin (HbA1c) level of 
5.7–6.4% [6]. The global increase of ductal adenocarcinoma of pancreas further 
escalates the need to understand the pathophysiology of Type 2 diabetes. Chronic 
Type 2 diabetes is established to be a risk factor for ductal adenocarcinoma of 
pancreas [7]. Type 2 diabetes is also linked with obesity, and obesity also increases 
the risk for developing ductal adenocarcinoma of pancreas [8]. Type 2 diabetes is 
also associated with defective insulin function since insulin fails to suppress hepatic 
glucose release. As a result, peripheral glucose utilization mainly by skeletal muscle, 
is compromised, with initial increase in insulin levels since the beta cells try to over-
come insulin resistance by producing more insulin [9]. With chronic Type 2 diabe-
tes, beta cells undergo failure leading to apoptosis and decreased beta cell mass [10]. 
Patients with obesity and Type 2 diabetes are likely to suffer for long time periods 
with high intrapancreatic insulin levels due to beta cell compensation to overcome 
the increasing insulin demand and to maintain glucose homeostasis. Insulin is 
released into the circulation by beta cells through intrapancreatic portal circula-
tion that also supplies blood to acinar and ductal cells near the islets. Acinar and 
ductal cells neighboring the islets may also get blood supply from intrapancreatic 
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portal circulation [11]. This close association allows high levels of islet hormones 
to directly get supplied to acinar and ductal cells, resulting in proxicrine effects 
on insulin receptors present on acinar cells and also on insulin like growth factor-I 
receptors in any differentiated cells in the region, enhancing survival and prolifera-
tion of the cells. Hence, intrapancreatic hyperinsulinemia, arising due to obesity 
and insulin resistance in prediabetic patients or in early diabetic patients contribute 
to increased risk in ductal adenocarcinoma of pancreas.
Compromised glycemic control is also associated with increased levels of 
advanced glycation end products (AGE) which activate RAGE, a receptor for AGE 
[12]. RAGE receptor belongs to the immunoglobulin super family and can bind 
to several ligands apart from AGE, including some proinflammatory cytokines 
that have role in inflammation and ductal adenocarcinoma of pancreas [12]. Also, 
activation of RAGE contributes to obesity and inflammation [13]. Excess of activa-
tion of RAGE also contribute to the higher prognosis of ductal adenocarcinoma of 
pancreas in Type 2 diabetes.
2. Mechanisms between type 2 diabetes and pancreatic cancer
The mechanism behind the association of Type 2 diabetes and pancreatic 
cancer is elaborate and include metabolic, hormonal, and immunological modifi-
cations that regulate tumor growth (Figure 1). The most presumed mechanisms 
behind the association between Type 2 diabetes and pancreatic cancer are insulin 
resistance, compensatory hyperinsulinemia and increased levels of circulating 
insulin-like growth factors (IGFs). In-vivo studies showed that islet cell turnover, 
linked with insulin resistance, is important for pancreatic cancer. Like, in hamsters, 
islet cell proliferation increase pancreatic ductal cancer [14], while destruction 
of islet cells by streptozotocin or alloxan impede pancreatic cancer prevalence 
[15, 16]. Also, biguanide metformin treatment inhibit the creation of pancreatic 
tumors by N-nitrosobis-(2-oxopropyl) amine, a potent pancreatic carcinogen. 
High-fat containing diet in hamsters normalize the islet cell turnover rate [17]. 
Figure 1. 
Association between diabetes and pancreatic cancer [1].
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Pancreatic β-cells become hyperactive, their mass increase which together led to 
insulin over secretion to combat insulin resistance. The exocrine part of pancreatic 
tissue is exposed to much higher level of local insulin concentrations than the 
amount of insulin in the circulation of hyperinsulinemic patients. Insulin also acts 
as a growth-promoting hormone which increases cell proliferation. Hence, insulin 
not only promotes cell proliferation but also increases uptake of glucose [18], and 
both of these processes are important for development and progression of tumor. 
Moreover, insulin increases the availability of insulin like growth factors by decreas-
ing hepatic production of binding proteins for insulin like growth factors [19, 20]. 
The two main properties of insulin like growth factor-1 (IGF-1) are mitogenic and 
antiapoptotic activities which increase growth of cells expressing insulin as well as 
IGF-1 receptor (IGF1R). Here it must be noted that IGF-1 and IGF1R are overex-
pressed in pancreatic cancer cells [21]. Also, IGF-1 regulated signal transduction 
elevates proliferation, invasion, and expression of different mediators of angio-
genesis and decrease apoptosis of pancreatic cancer cells as well [22–24]. IGF1R-
induced signal transduction also activates several intracellular signal pathways, 
like Ras/Raf/mitogen-activated protein kinase and phosphoinositide-3 kinase/Akt/
mammalian target of rapamycin (mTOR) pathways [25]. Decreased levels of IGF 
binding protein 1 can predict increased risk of pancreatic cancer [26]. Unusual 
glucose metabolism can also predict presence of tumor cells, since most tumors 
have upregulated insulin-independent glucose uptake mechanisms while, diabetic 
animals with β-cell destruction induced by alloxan show reduced tumor growth 
[27]. This suggests that hyperglycemia has no role in increasing neoplastic growth 
in insulin deficiency. High dietary glycemic index increases the risk of pancreatic 
cancer due to deleterious effects of high postprandial glucose and increasing insulin 
demands [28]. Type 2 diabetes and diabetes associated obesity increase the risk of 
pancreatic cancer due to increased oxidative stress and inflammation during type 
2 diabetes and also due to the link between oxidative stress and insulin resistance 
[29–32]. Antioxidant supplementation with vitamin E or α-lipoic acid can be 
preventive or curative in insulin resistance [33, 34]. Moreover, postprandial hyper-
glycemia directly increases oxidative stress leading to overproduction of superoxide 
by the mitochondrial electron-transport chain [35]. Impairment of the cellular 
redox state reduces tyrosine phosphorylation and elevates serine phosphorylation 
of insulin receptor substrate 1, which leads to impaired insulin-signaling pathway 
[35]. Moreover, obesity and macronutrient intake activate inflammatory signaling 
pathways [36, 37], and glucose and fat intake stimulate inflammation by increasing 
oxidative stress and the activating transcriptional factors such as nuclear factor-κB, 
activating protein-1 and early growth response-1 [38–40]. Also, adipose tissues 
may act as an endocrine organs to regulate the release of fatty acids, hormones, and 
cytokines like tumor necrosis factor-α, interleukin-6, and resistin [41].
Adipocytokines, which are secreted from adipocytes, are mainly involved 
in apoptosis, development, metabolism, innate immunity and inflammation. 
Proinflammatory cytokines are known to stimulate angiogenesis, tumor pro-
gression, and metastasis. During obesity or Typ2 2 diabetes altered levels or 
dysfunctions of many molecules like leptin [42], IGF-1 [43], and peroxisome 
proliferator-activated receptor-γ [44], lead to development of pancreatic cancer by 
impeding immune system.
Several genome-wide studies have shown new genetic variants that increase the 
risk of diabetes, and some of the susceptible loci already established in Type 2 dia-
betes are known to be involved in differentiation and development [45]. NR5A2 (or 
LRH1) is one such pancreatic cancer susceptibility gene identified in genome-wide 
association studies [46]. NR5A2 is a direct target of pancreatic duodenal homeobox 
(PDX-1) gene in pancreatic development and differentiation [47]. It regulates the 
5
Islet Inflammation: The Link between Type 2 Diabetes and Pancreatic Cancer
DOI: http://dx.doi.org/10.5772/intechopen.98538
expression of developmental genes, like transcription factors hepatocyte nuclear 
factor (HNF)-3β, HNF-4α, and HNF-1β. On the other hand, NR5A2 expression 
is regulated by HNF-3β and HNF-1, so the case is regulated both ways. PDX-1 is 
necessary for pancreatic development and also for casual function of β-cell and 
secretion of insulin [48]. Mutations in HNF-1β gene is associated with maturity-
onset diabetes in the young people [49]. Better insight about the function of NR5A2 
gene in the progression and development of pancreatic cancer can be helpful in 
curbing the risk of diabetes-linked pancreatic cancer and also decipher the genetic 
mechanisms behind Type 2 diabetes and pancreatic cancer.
2.1  Genomic associations between type 2 diabetes, chronic pancreatitis and 
pancreatic ductal adenocarcinoma
Several clinical and epidemiological studies associate the risk of ductal adeno-
carcinoma of pancreas to chronic Type 2 diabetes and chronic pancreatitis (CP). 
The genetic reasons of susceptibility among all these three diseases are quite variant 
however, some reasons are common. The mechanism behind the function of these 
genes and how they influence susceptibility is not common because of the differ-
ence in methodology of identification of the genes. Interestingly, all three diseases 
share these characteristics: 1) all patients have a report of family history or familial 
clustering, which indicate shared genetic or environmental influence, 2) differ-
ence in age of patients at the time diagnosis is due to familial risk, and 3) analyz-
ing Mendelian segregation prove that in some families there are some hereditary 
components which demonstrate the common features of the gene [11]. Apart from 
genetics factors, there are epidemiological factors like obesity in diabetes, alcohol 
intake in chronic pancreatitis, and smoking in ductal adenocarcinoma of pancreas 
that may work with genetic factors to increase the risk. Several approaches have 
been evolved to discover these susceptibility genes, from family-based case control 
studies and cohort studies, from where a list of candidate genes is identified, and 
large-scale genome-wide association studies (GWAS) are conducted to search 
for single nucleotide polymorphisms (SNPs) or next-generation sequencing. The 
genetic basis of Type 2 diabetes is characterized as polygenic, having implication of 
over 50 genes [50]. Any single major gene cannot explain the genetic risk of Type 
2 diabetes except in some rare cases [51]. However, chronic pancreatitis and ductal 
adenocarcinoma of pancreas can be explained by mutations in some major genes. 
Genome-wide association studies (GWAS) have identified many low-penetrance 
common SNPs which are associated with risk of ductal adenocarcinoma of pan-
creas. Among all these three diseases, Type 2 diabetes has been studied in detail, 
which depict that Type 2 diabetes is a multifactorial disease and is genetically com-
plex. Variants of more than 50 genes have been studied which increase genetic risk. 
These genes are divided into some having modest effect like PPARG and KDNJ11, 
and others having strong association like TCF7L2, WFS1, HDF1B, FTO, CDKN2A, 
and SLC20A8. New strategies have been developed which have characterized the 
genetic basis of the disease through subclinical or related phenotypes by predis-
position of the genes [52]. Since Type 2 diabetes is a polygenic risk model, each 
genetic variant has a small effect. These genetic variants improve risk assessment 
from common risk factors like age, sex, family history and BMI (Body Mass Index) 
[53]. Family-based studies and data on pathophysiology of chronic pancreatitis 
facilitate success in explaining the genetic heterogeneity [54]. Most of the variations 
in susceptibility are due to acute and chronic pancreatitis being related to genetic 
variations among patients. Alcohol was considered to be the primary reason behind 
genetic contributions but after the discovery of PRSS1, CFTR, and SPINK1 variants 
which associated with pancreatitis the reasons have been resolved [55]. Hence, no 
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single factor can cause pancreatitis, and majority of cases having acute and chronic 
pancreatitis have multiple variants of a gene, or multiple genes having epistatic 
interactions, or genetic factors coupled with environmental cues.
The genetic predisposition to ductal adenocarcinoma of pancreas is difficult due 
to the poor collection and analysis of biospecimens from patients owing to their 
low survival rate. Alike Type 2 diabetes and chronic pancreatitis, ductal adenocar-
cinoma of pancreas is also genetically heterogeneous. The identification of suscep-
tibility genes has led to discovery of some rare gene mutations which are associated 
with cancer syndromes linked with common single nucleotide polymorphisms 
(SNPs). Study designs on family hierarchy and case-controls have led to discovery 
of mutations in known syndrome-associated genes, like BRCA1, BRCA2, CDKN2A, 
and CFTR. Moreover, next-generation sequencing has led to identification of 
additional mutations like PALB2 [56] and ATM [57]. Patients with sporadic ductal 
adenocarcinoma of pancreas carry germline mutations in major genes [58] and it 
changes the present knowledge for risk assessment. Large numbers of sporadic cases 
of ductal adenocarcinoma of pancreas and healthy subjects have exposed SNPs 
in chromosomal regions containing ABO, TERT, and CLPTM1L and other genes. 
Nevertheless, risk modeling using GWAS SNPs cannot provide sufficient genetic 
information that can improve prediction of pancreatic cancer [59].
2.2  Role of obesity and pancreatitis mediated inflammation in pancreatic ductal 
adenocarcinoma
Obesity is linked with an elevated risk of cancer, including pancreatic cancer 
[60]. The observed increase in pancreatic cancer epidemiology and deaths can be 
partially attributed to obesity taking the form of an endemic disease. Obesity can 
lead to pancreatic cancer, insulin resistance, hyperinsulinemia and inflammation 
by many possible ways [61]. Pancreatic cancer development can be attenuated in 
genetically engineered mouse model by using nonsteroidal anti-inflammatory 
drugs, which indicate that tissue inflammation plays an important role in this dis-
ease [62]. Tissue inflammation during obesity creates a perfect microenvironment 
for tumor initiation and promotion. Besides obesity, increase in BMI and visceral 
adiposity bears a strong link with metabolic diseases and gastrointestinal cancers, 
together with pancreatic cancer [63]. The accumulation of adipose tissue near the 
pancreas (peri-pancreatic depot) lead to an enhanced proinflammatory reaction 
in response to high-fat or high-calorie containing diet compared to peri-gonadal 
depot [64]. The association between adipose tissue depot-specific reactions to diet-
induced obesity and the effect of these adipose tissue depots on cancer development 
is very crucial to understand the connection between body condition and risk of 
cancer. Moreover, high-fat or high-calorie containing diet increases the progression 
of pancreatic intraepithelial neoplasia, which is a known precursor of ductal adeno-
carcinoma of pancreas, and this accelerates the incidence of pancreatic cancer in an 
invasive and metastatic manner in conditional KrasG12D mouse model [65, 66].
2.3 Mechanisms behind type 2 diabetes in pancreatic ductal adenocarcinoma
To be specific, prevalence of Type 2 diabetes among ductal adenocarcinoma 
of pancreas patients is really very high. Type 2 diabetes is found in 47% of ductal 
adenocarcinoma of pancreas patients compared with only 7% of healthy subjects, 
and a normal fasting glucose occurs in 59% of healthy subjects, while it is found 
only in 14% of ductal adenocarcinoma of pancreas patients [5] (Figure 2). In 74% 
of ductal adenocarcinoma of pancreas patients with diabetes, diabetes is diagnosed 
within 24 months before the diagnosis of ductal adenocarcinoma of pancreas [67]. 
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This remarks that in most of the patients, new-onset diabetes is due to the tumor 
and this diagnosis of diabetes may be a useful “biomarker” for the diagnosis of duc-
tal adenocarcinoma of pancreas. Although known risk factors for Type 2 diabetes 
like obesity, age and family history of diabetes are also the common risk factors in 
case of risk factors for ductal adenocarcinoma of pancreas, the occurrence of Type 2 
diabetes in ductal adenocarcinoma of pancreas is pretty higher than the occurrence 
of Type 2 diabetes among all other common types of cancer. Type 2 diabetes is 
found in 68% of patients with ductal adenocarcinoma of pancreas while it occurs 
in 14.8–23.5% of patients with breast, colon, lung, and prostate cancers [68]. Also, 
insulin resistance is common in patients with both ductal adenocarcinoma of 
Figure 2. 
Prevalence of type 2 diabetes in ductal pancreatic adenocarcinoma [5, 11].
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pancreas and Type 2 diabetes, while many patients with ductal adenocarcinoma of 
pancreas undergo weight loss. Deteriorating glycemic control along with weight 
loss occurs in ductal adenocarcinoma of pancreas along with its incidence in Type 2 
diabetes. These common characteristics give alert to the clinicians for the possibility 
of ductal adenocarcinoma of pancreas -associated diabetes. New-onset diabetes 
associated with ductal adenocarcinoma of pancreas can be cured after tumor resec-
tion, if there are enough islets left in the pancreatic tissue. Several reports show 
that Type 2 diabetes improves after resection of pancreatic tumors [69]. 57% of the 
patients with new-onset diabetes get cured of diabetes post operation of pancreatic 
tumors, while all of ductal adenocarcinoma of pancreas patients with long-standing 
diabetes cannot be cured of diabetes even after pancreatic resection [5] (Figure 3). 
These data strongly support that new-onset diabetes is associated with ductal 
adenocarcinoma of pancreas and it can be a paraneoplastic phenomenon, where 
malignancy interferes with insulin secretion or insulin function, finally leading to 
Type 2 diabetes. Numerous studies have tried to identify the mechanisms behind 
Type 2 diabetes caused by ductal adenocarcinoma of pancreas or the genomic and 
protein markers of Type 2 diabetes caused by ductal adenocarcinoma of pancreas. 
Connexin 26, a gap junction protein, is highly overexpressed in islets of ductal 
adenocarcinoma of pancreas patients with Type 2 diabetes [70], and a pancreatic 
ductal adenocarcinoma -derived S-100A8 N-terminal peptide is a diabetogenic 
agent [71, 72] which is also upregulated patients with ductal adenocarcinoma of 
pancreas associated with new-onset diabetes. Vanin-1 and matrix metalloprotein-
ase 9 can also act as predictors of ductal adenocarcinoma of pancreas associated 
diabetes [73]. Vanin-1, is also overexpressed during inflammation, which means 
that mediators of inflammation play an important role in damaged islet function 
and insulin function in ductal adenocarcinoma of pancreas. Pancreatic Polypeptide 
(PP) release increases in Type 2 diabetes, and a deficit in PP response due to nutri-
ent ingestion can transform into new-onset diabetes caused by pancreatic exocrine 
Figure 3. 
Prevalence of type 2 diabetes after pancreaticoduodenectomy for ductal pancreatic adenocarcinoma [5, 11].
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disease. Basal and meal-stimulated PP release significantly decreases in patients 
with diabetes associated with ductal adenocarcinoma of pancreas localized in the 
head of pancreas in comparison to patients with Type 2 diabetes [11].
2.4 Significance of type 2 diabetes in pancreatic ductal adenocarcinoma
Some researchers say that diabetes does not contribute to earlier diagnosis or 
clinical features or tumor size or prognosis of pancreatic cancer [74], although, 
previous studies had established that diabetes can predict pancreatic cancer [75]. 
A study compared diabetic and non-diabetic patients and observed a worse overall 
mortality and median survival in diabetic patients [76]. In another study, patients 
with diabetes had a better overall survival [77]. On the other hand, Type 2 diabetes 
is known to confer a poor survival in ductal adenocarcinoma of pancreas patients 
[78]. Actually, gender and mean age of the patients in these two studies regulated 
the number of comorbidities, time of diabetes and also time for development of 
complications in diabetes [75]. Use of preventive medicine, frequent clinical follow-
up and earlier diagnosis of ductal pancreatic adenocarcinoma can generate a better 
median survival.
3. Future perspectives of dealing with pancreatic ductal adenocarcinoma
The explanation of hormonal [79], paracrine [21] and autocrine [22, 23] media-
tors of pancreatic cancer and its association with new-onset diabetes can be helpful 
in pathogenesis and showing new therapeutic targets. A better explanation of the 
epidemiology of pancreatic cancer, is poorly controlled diabetes or it can be an 
intrinsically genetic [8] or epigenetic [80–82] or immunologic [83, 84] or gastroin-
testinal microbiota [85, 86] or tissue microenvironment which are characteristic of 
Type 2 diabetes [87–89] patients progressing towards pancreatic cancer.
The various techniques like gene sequencing, lymphocyte flow cytometry, 
mRNA profiling, PCR studies and microbe identification microarray from Type 
2 diabetes patients in different stages of progression can help in early diagnosis 
and prevent diabetic complications in pancreatic cancer and diabetes. Molecular 
biomarkers can be very crucial to diagnose patients with new-onset diabetes who 
should be tested with endoscopic ultrasound for identifying pancreatic cancer [75]. 
Hyperinsulinemia can negatively predict value development of new-onset diabetes 
associated with pancreatic cancer if all other hormonal, paracrine or autocrine 
factors play against development of insulin resistance [75].
Metformin, a well-known medication for Type 2 diabetes, improves survival in 
pancreatic cancer patients and has prognostic effects [90]. The knowledge available 
on the mechanism of action of metformin helps in the understanding of the ductal 
adenocarcinoma of the pancreas cancer pathways [75].
4.  Altered intracellular metabolism in pancreatic ductal 
adenocarcinoma
Deregulated systemic physiology is the effect of disruption of energy homeo-
stasis, and metabolic processes within the cells of a pancreatic tumor can also be 
knowledgeable [91]. Malignant cells of a pancreatic tumor, have alterations that 
are mediated by both oncogene-driven programs and also by the rare physiology 
of tumor. Pancreatic tumors have a dense, fibrotic stroma which inhibits vascular 
function and also disrupts delivery of nutrients and oxygen [92]. Mutant Kras 
Inflammation
10
expression regulates metabolic networks facilitating redox balance, bioenerget-
ics, and anabolic metabolism for better survival and cell proliferation under these 
poor circumstances [93–95]. Nutrients recycled by autophagy fuel these pathways 
[96, 97] and also the nutrients scavenged by nonspecific bulk extracellular space 
engulfment or by micropinocytosis [98] as well as overexpressed nutrient importers 
help in regulating these pathways [93, 99]. Together, the regulation of metabolism 
of pancreatic cancer cells are controlled by oncogene-driven pathways, and they 
engage nutrient scavenging mechanisms as well as improve nutrient utilization to 
overcome the problems of insufficient vascularization [91].
Malignant cells constitute 10% of the total cellular content of a pancreatic tumor 
[92]. As a result, the non-malignant cells help in shaping the metabolic condition 
and facilitate tumor growth [91]. These processes can be divided into 2 types: First, 
the cooperative reactions between non-malignant cells and malignant cells support 
the metabolism in cancer cells, and second, the reaction between malignant and 
non-malignant cells is competitive and it happens between tumor cells and the 
antitumor immune reaction [100].
One main cooperative reaction is the nutrient exchange pathway that occurs 
between pancreatic cancer cells and activated pancreatic stellate cells (PSCs) 
[101]. Pancreatic cancer cells are known to induce autophagy in the PSCs. As a 
result, protein breakdown occurs through autophagy and nonessential amino acids 
are released. Now, the pancreatic cancer cells engulf alanine and utilize it to in 
mitochondrial metabolism and also in the biosynthesis of cellular building blocks. 
Here it must be mentioned that alanine can be used in metabolism in replacement 
of glucose and glutamine, and the biosynthetic substrates also aid in cancer cell 
metabolism. If this metabolic crosstalk pathway is blocked or inhibited by suppress-
ing autophagy particularly in the PSCs then it can lead to a dramatic decrease in 
tumor growth. Interestingly, pancreatic tumors can suppress immune responses and 
are highly resistant to immunotherapies [102]. Local nutrient depletion and waste 
accumulation indeed play important roles in aiding tumor immune suppression 
[100]. Moreover, Cytotoxic T-cells, are intrinsically less apt at obtaining nutrients 
than oncogene-driven cells, and they are compelled to compete for the limited 
nutrients like carbohydrates and amino acids, in a tumor microenvironment, and 
later result in defective antitumor immune response. The compromised antitu-
mor T-cell response in melanoma and sarcoma is directly connected with glucose 
deprivation [103, 104], while high titres of lactate aid in the polarization of anti-
inflammatory macrophages [105]. Mutant Kras-expressing pancreatic cancer cells 
vigorously consume glucose and then release lactate (so-called, Warburg metabo-
lism) [93], and all of these mechanisms result in suppressed immune function in 
pancreatic cancer. Moreover, M2 type anti-inflammatory macrophages and cancer 
cells can exhaust tumors of amino acids such as arginine and tryptophan [106]. 
These processes also restrict antitumor T-cell responses and aids the differentiation 
of T-cells into anti-inflammatory T-regulatory cells.
5.  Role of bariatric surgery in obesity and pancreatic ductal 
adenocarcinoma
Premorbid obesity unpleasantly influences ductal adenocarcinoma of pancreas 
associated mortality in a dose-dependent manner [107, 108]. A high BMI is also 
linked with an increased risk of ductal adenocarcinoma of pancreas [107, 108]. 
The etiology of obesity-linked diseases starts with excess energy and deposition of 
triglyceride in the adipose tissue. This excess of triglyceride cannot be completely 
deposited in the adipose tissue, hence ectopic fat deposition occurs in various 
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organs like liver and pancreas. Triglyceride deposition in the liver leads to oxidative 
stress and inflammation, resulting in cirrhosis, steatohepatitis and hepatocellular 
carcinoma. Similar mechanisms occur in the pancreas. Free fatty acids and inflam-
matory mediators remain in high amounts in the pancreas of obese high fat fed mice 
[109], and this accelerates tumor growth [110]. Fat depots in liver and pancreas 
increase in obese individuals. After bariatric surgery, weight loss occurs, and 
hepatic and pancreatic fats rapidly disappear [111]. After weight loss, insulin resis-
tance and circulatory levels of inflammatory factors also rapidly normalize [112]. 
Weight loss occurring after bariatric surgery decreases cancer mortality by 40–60% 
[113, 114]. Also, the risk of ductal adenocarcinoma of pancreas is significantly lower 
among the patients who have undergone bariatric surgery [115]. Nevertheless, bar-
iatric surgery is restricted to individuals with high obesity (mean BMI >40 kg/m2). 
Substantial weight loss (mean > 30% total body weight) occurs in these individuals 
after bariatric surgery. Moreover, intentional weight loss by bariatric surgery or 
changes in lifestyle or pharmacotherapy or less invasive surgical or endoscopic 
procedures also helps in reducing the risk of cancer in obese patients [115].
6.  Role of visceral and Peripancreatic fat in pancreatic ductal 
adenocarcinoma
BMI is a well-known marker for adiposity, and can also be linked with insulin 
resistance, metabolic syndrome and gastrointestinal malignancies, like ductal 
adenocarcinoma of pancreas [116]. Highly inflamed visceral adipose tissue (VAT) in 
obese patients remains the main reason behind metabolic dysfunction and gastro-
intestinal cancer due to the close proximity of the visceral organs with the portal 
system. VAT has a high correlation with occurrence of ductal adenocarcinoma of 
pancreas. Interestingly, conditional KRasG12D (KC) mice fed high-fat and high 
calorie containing diet gained more weight than the standard diet fed mice and 
ended up developing hyperinsulinemia and hyperleptinemia with extensive VAT 
expansion and high inflammation [64, 65, 117]. These obese KC mice had highly 
inflamed pancreas and were more prone to develop ductal adenocarcinoma of 
pancreas than the control mice fed on standard diet and this occurred in the male 
mice, which meant that the sex hormones had a role in it [117]. Interestingly, the 
increased incidence of pancreatic ductal adenocarcinoma in obese KC mice was 
largely seen in male mice, suggesting a role for sex hormones in this process, since 
the female mice gained more adipose tissue subcutaneously [64, 65, 117].
7. Role of gut microbiome in pancreatic ductal adenocarcinoma
Human microbiome has gained a lot of popularity recently to tackle prevention, 
as well as early diagnosis, and treatment of ductal adenocarcinoma of pancreas, 
since many diseases have now started to be linked with composition of microbiome 
[118–120]. The composition of microbiome also interferes with development of 
ductal adenocarcinoma of pancreas and its relation with diabetes, obesity, and 
inflammation [121]. Ductal adenocarcinoma of pancreas is an inflammation-medi-
ated cancer and gut microbiome can stimulate chronic inflammation via changes 
in molecular pattern recognition receptors. These pattern recognition receptors 
and their downstream signaling cascade leads to the incidence of inflammation-
mediated cancers. These bacteria regulate the efficiency of calorie absorption in the 
intestines and hence lead to obesity. Many diseases like Type 2 diabetes, obesity, 
and chronic pancreatitis are linked with chronic inflammation, which also result in 
Inflammation
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ductal adenocarcinoma of pancreas [122]. Moreover, alteration of oral microbiome 
increases risk of ductal adenocarcinoma of pancreas, and it can be a useful bio-
marker of the disease. Specific abundance in certain oral bacteria and gut microbi-
ome in pancreatic secretions or fecal matter may be associated with risk of ductal 
adenocarcinoma of pancreas, hence these knowledges can help in preventing or in 
early diagnosis of ductal adenocarcinoma of pancreas [122].
8. Role of inflammation in pancreatic ductal adenocarcinoma
As already mentioned above, chronic inflammation in pancreas or chronic 
pancreatitis is a major reason behind ductal adenocarcinoma of pancreas. Activated 
PSCs play a key role in progression of chronic pancreatitis. Activation of PSCs 
is also increased by cytokines secreted from injured acinar and immune cells. 
The mechanisms underlying triggering of macrophages and survive the fibrotic 
processes by reacting with PSCs, if interfered end in suppression of inflammation 
and fibrosis in chronic pancreatitis [123]. Alcohol and smoking are also potent 
risk factors for chronic pancreatitis and ductal adenocarcinoma of pancreas. IL-22 
signaling during inflammation and cross talk between immune cells and PSCs is one 
of the signaling involved in smoking-induced progression of chronic pancreatitis 
[124]. The other pathways that are behind progression of ductal adenocarcinoma of 
pancreas are IL-6 and histone deacetylases in immune and cancer cell interactions, 
which together mean that immune signals are key factors in promoting pancreatitis 
and pancreatic cancer progression [125]. However, most cases of ductal adeno-
carcinoma of pancreas are resistant to immunotherapies treatment with immune 
checkpoint antibodies because inflammatory processes are important in promoting 
the malignant transformation, growth, and metastasis of pancreatic cancer. For 
example, Kras mutations stimulate profuse cytokine and chemokine secretion 
in tumor epithelial cells and recruit immune cells like macrophages, dendritic 
cells (DCs), and myeloid-derived suppressive cells, all of which stimulate tumor 
growth and progression. So, all these cells need to be reprogrammed in ductal 
adenocarcinoma of pancreas to create a favorable immunostimulatory environment 
for efficient immunotherapy. Since, ductal adenocarcinoma of pancreas is often 
followed by metastatic relapse even after complete surgical pancreatic resection, 
the newly developed cancer cells fail in immunotherapy, which means that a better 
knowledge about the factors affecting metastasis is important for the development 
of more effective immunotherapies and treatments [126]. Early metastases are 
linked with dense networks of CD11b + CD11c + MHC-II + CD24 + CD64 and low 
F4/80 cells, and all of these cells develop from monocytes and aid in promoting 
metastasis by increasing regulatory T-cells and suppressing the development of 
cytotoxic T-cells. Phenotypically similar dendritic cells are seen to accumulate at 
primary and secondary sites in pancreatic portions of ductal adenocarcinoma of 
pancreas patients [127]. Dendritic cells can be reprogrammed into immunostimula-
tory antigen-presenting cells in tumor metastasis, which is one of the most popular 
immunotherapeutic strategies at present. Another strategy is based on the avail-
ability of tumor-binding immunoglobulin G antibodies along with some dendritic 
cell-stimulating molecules which help the enable tumor-associated dendritic cells 
to uptake, process, and present a variety of tumor antigens to T-cells. Then the 
T-cells proliferate and attack the tumors throughout the host. This technique can 
eradicate metastases, and also primary tumors in many types of cancers, including 
ductal adenocarcinoma of pancreas by overcoming tumor-mediated immunosup-
pression [128]. But the tumor cells tend to enter into the circulation and metastasize 
and end up colonizing distant organs [129]. Metastatic ductal adenocarcinoma of 
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pancreas has many epigenetic modifications in the primary tumor. While the cancer 
cells circulate in clusters and colonize different organs, the establishment of a new 
premetastatic niche in a new organ includes proinflammatory processes, exosomes 
and immune cells [130]. All of this information can help in developing new thera-
peutic approaches targeting different agents for primary ductal adenocarcinoma of 
pancreas and also in its metastasis.
9. Conclusion
Ductal adenocarcinoma of pancreas is a very challenging malignancy with a high 
incidence and high lethality. Moreover, the disease has intricate relationships with 
diabetes and obesity. Type 2 diabetes has its own risks and can be both a risk factor 
for ductal adenocarcinoma of pancreas as well as an early manifestation of the 
disease. Obesity is also strongly associated with increasing risk of ductal adenocar-
cinoma of pancreas. However, every detail about all these diseases and their associa-
tion is not fully understood, particularly the specific mechanisms that contribute 
to ductal adenocarcinoma of pancreas are not clear, which makes the diagnosis 
and treatment of ductal adenocarcinoma of pancreas very difficult. Hence present 
research is targeted in bringing out all the minute details and the mechanisms to 
tame this malignancy and preferably find a cure or a preventive mechanism or at 
least a better biomarker in near future.
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